| 31 | 0 | 56 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 观察μ阿片受体（OPRM1） A118G基因多态性对壮族肺癌患者肺叶切除术后镇痛效果的影响。方法 选取行肺叶切除术的广西壮族肺癌患者84例为研究对象，根据OPRM1 A118G基因多态性分为AA组（野生纯合子型，n=53）、AG组（杂合子型，n=22）和GG组（突变纯合子型，n=9）。三组均行肺叶切除术，术中予相同麻醉诱导和麻醉维持，术毕连接自控静脉镇痛，观察并记录三组术后2、6、12、24、48 h时视觉模拟评分（VAS），记录三组术后镇痛泵按压次数、舒芬太尼消耗剂量，观察术后不良反应发生情况。结果 三组术后不同时间VAS比较差异均无统计学意义（P均>0.05）。与AA组比较，AG组术后镇痛泵按压次数多、舒芬太尼消耗剂量大（P均<0.05）；与AG组、AA组比较，GG组术后镇痛泵按压次数多、舒芬太尼消耗剂量大（P均<0.05）。三组术后不良反应发生情况差异无统计学意义（P均>0.05）。结论 OPRM1 A118G G等位基因的壮族肺癌患者在肺叶切除术后舒芬太尼镇痛的需求量较高。
Abstract：Objective To investigate the effect of μ-opioid receptor(OPRM1) A118G gene polymorphism on postoperative analgesia in lung cancer patients of Zhuang ethnic group undergoing lobectomy. Methods Eighty-four Zhuang lung cancer patients undergoing lobectomy in Guangxi were enrolled and divided into three groups based on OPRM1A118G genotypes: AA group(wild-type homozygotes, n=53), AG group(heterozygotes, n=22), and GG group(mutant homozygotes, n=9). All groups underwent lobectomy and received identical anesthesia induction/maintenance protocols during operation and patient-controlled intravenous analgesia postoperatively. Visual Analog Scale(VAS) scores at 2, 6, 12, 24, and 48 h after operation were recorded, along with analgesic pump demands, sufentanil consumption, and adverse effects. Results No significant differences were observed in VAS scores at different time points among these three groups(all P>0. 05). Compared with AA group, AG group demonstrated significantly higher analgesic pump demands and sufentanil consumption(both P<0. 05). GG group required significantly more pump demands and sufentanil than both AG and AA groups(all P<0. 05). There were no significant differences in the adverse events among these three groups(all P>0. 05). Conclusion Zhuang lung cancer patients carrying OPRM1 A118G G allele require higher sufentanil doses for post-lobectomy analgesia.
[1] CREWS K R, MONTE A A, HUDDART R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6,OPRM1, and COMT genotypes and select opioid therapy[J].Clinic Pharmacolo Therapeut, 2021, 110(4):888-896.
[2]张双全，王刚，李少英，等.广东女性人群μ受体基因118A→G突变对吗啡镇痛效果的影响[J].实用医学杂志，2012,28(22):37-43.
[3] YEE L, CAPULE F R, MAKMOR-BAKRY M. Genetic polymorphisms of OPRM1 on the efficacy and safety of anesthetic and analgesic agents:a systematic review[J]. Pharmacogenomics,2022, 23(10):609-617.
[4] SPAMPINATO S M. Overview of genetic analysis of human opioid receptors[J]. Methods Mol Bio, 2021, 2021:3-13.
[5] HERTZ D L, RAMSEY L B, GOPALAKRISHNAN M, et al. Analysis approaches to identify pharmacogenetic associations with pharmacodynamics[J]. Clinic Pharm Ther,2021, 110(3):589-594.
[6]刘虹新，陈东旭，李茜.术后阿片类药物长期使用的研究进展[J].山东医药，2023,63(31):92-97.
[7] ANNIS A C, GUNASEELAN V, SMITH A V, et al. Genetic associations of persistent opioid use after surgery point to oprm1 but not other opioid-related loci as the main driver of opioid use disorder[J]. Gene Epidemiolo, 2025, 49(1):22588.
[8] HERTZ D L, RAMSEY L B, GOPALAKRISHNAN M, et al.Analysis approaches to identify pharmacogenetic associations with pharmacodynamics[J]. Clinic Pharm Ther, 2021, 110(3):589-594.
[9] WONG A K, SOMOGYI A A, RUBIO J, et al. The role of pharmacogenomics in opioid prescribing[J]. Curr Treat Options Onco, 2022, 23(10):1353-1369.
[10] HARTWELL E E, FEINN R, MORRIS P E, et al. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder[J]. Addiction, 2020, 115(8):1426-1437.
[11]陈楠.新疆女性CYP3A4*1G、OPRM1 A118G基因多态性与舒芬太尼术后镇痛的关系[D].乌鲁木齐：新疆医科大学，2020.
[12] NIU H, ZHAO S, WANG Y, et al. Influence of genetic variants on remifentanil sensitivity in Chinese women[J]. Jour Clinic Pharm Ther, 2022, 47(11):1858-1866.
[13]潘凤婷.桂西地区壮族女性患者OPRM1 A118G基因多态性与舒芬太尼术后镇痛效应的相关性研究[D].南宁：广西医科大学，2020.
[14] BAGHER A M, HAREERI R H. Allele frequency and genotype distribution of the opioid receptorμ-1(OPRM1)A118G polymorphism in the western saudi population[J]. Jour App Bio, 2023,21(3):160-165.
[15] FRANGAKIS S G, MACEACHERN M, AKBAR T A, et al. Association of genetic variants with postsurgical pain:a systematic review and meta-analyses[J]. Anesthesiology,2023, 139(6):827-839.
[16] LI Z X, YE F, LI W Y, et al. The effect of genetic variation on the sensitivity to opioid analgesics in patients with postoperative pain:an updated meta-analysis[J]. Pain Phy, 2023, 26(5):467-485.
[17]陈思，刘瞾宇，曾毅，等. OPRM1A118G多态性对喉癌患者术后舒芬太尼静脉自控镇痛效果的影响[J].西部医学，2018, 30(11):1589-1592.
[18] ZHOU Y, CAO L, YANG Y, et al. Is OPRM1 genotype a valuable predictor of VAS in patients undergoing laparoscopic radical resection of colorectal cancer with fentanyl[J]. BMC Anesth,2023, 23(1):173.
[19] HUANG D, LUO Z, SONG X, et al. Global research on sufentanil use in anesthesiology from 2003 to 2023:a bibliometric analysis[J]. Frontiers Pharm, 2024, 15:1412726.
[20]王军，赵霞，刘长宏. 37例肋骨内固定术后自控镇痛泵应用观察[J].山东医药，2013,53(31):46-48.
[21] DOUVILLE N J, BASTARACHE L, HE J, et al. Polygenic score for the prediction of postoperative nausea and vomiting:a retrospective derivation and validation cohort study[J]. Anesthesiology, 2025, 142(1):52-71.
[22] DARVALL J, HANDSCOMBE M, MAAT B, et al. Interpretation of the four risk factors for postoperative nausea and vomiting in the Apfel simplified risk score:an analysis of published studies[J]. Can J Anaesth, 2021, 68(7):1057-1063.
[23] AROKE E N, HICKS T L. Pharmacogenetics of postoperative nausea and vomiting[J]. J Perianesth Nurs, 2019, 34(6):1088-1105.
[24] DUNN K E, HUHN A S, FINAN P H, et al. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids:a human laboratory phenotype-genotype assessment[J]. Addiction Bio, 2024, 29(1):13355.
[25] PLANELLES B, MARGARIT C, INDA M D, et al. Gender based differences, pharmacogenetics and adverse events in chronic pain management[J]. Pharmacogenomics J, 2020, 20(2):320-328.
基本信息:
DOI：
中图分类号:R614;R734.2
引用信息:
[1]曾春陆,黄格,阮浩神等.μ阿片受体A118G基因多态性对壮族肺癌患者肺叶切除术后镇痛效果的影响[J].山东医药,2025,65(05):24-27.
基金信息:
广西自治区卫健委科研项目（Z20210292）